NCT05475119

Brief Summary

The participants whom undergo Polysomnography study (Sleep study) and are found to have mild, moderate or severe Obstructive Sleep Apnea (OSA) will have two consecutive titration nights. Randomly, they'll do (CPAP) titration followed by (HFNC) titration or vice versa. To explore the possibility of the CPAP not being superior to HFNC in reduction of sleep apnea events.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jun 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2022

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

June 22, 2022

Completed
1 month until next milestone

First Posted

Study publicly available on registry

July 26, 2022

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2022

Completed
29 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2022

Completed
Last Updated

July 26, 2022

Status Verified

July 1, 2022

Enrollment Period

6 months

First QC Date

June 22, 2022

Last Update Submit

July 24, 2022

Conditions

Outcome Measures

Primary Outcomes (3)

  • Apnea/Hypopnea Index count using High Flow Nasal Cannula oxygen device and Continuous Positive Pressure Airway device on patients with Obstructive Sleep Apnea

    the Apnea/Hypopnea Index (AHI) is 5 events or less

    two nights

  • Sleep architecture while using High Flow Nasal Cannula oxygen device

    Standard sleep architecture: sleep breathing disorder e.g. apnea, hypopnea, snoring Oxygenation : minimum oxygen saturation, duration of desaturation and number of desaturation Arousals : number and index

    two nights

  • Tolerance and acceptability of High Flow Nasal Cannula by patients compared to the standard Continuous Positive Airway Pressure

    Comparison of High Flow Nasal Cannula device compared to the Continuous Positive Airway Pressure for a long term usage; being assessed in 1. How well did you accept the device yesterday? 2. How comfortable was the usage of the device? 3. Was the used mask comfortable? (1)not acceptable, (2)tolerable, (3)acceptable, (4)well received, (5)excellent 4. Did you face any difficulties breathing through your nose while using the device last night? 5. Did you have any of these symptoms while using the mask last night? Nasal dryness, Mouth dryness, Runny nose, Fear or anxiety, Congested nose 6. Did you feel any air leakage from the mask last night ? 7. Was it hard keeping the mask on while sleeping? 8. Are you prepared to use the CPAP machine as a therapy daily?

    two nights

Secondary Outcomes (1)

  • Changes in sleep structure compared to the diagnostic night

    two night

Study Arms (1)

Participants diagnosed with Obstructive Sleep Apnea

EXPERIMENTAL

The participants will sleep three nights at the sleep lab and undergo in their first night, Polysomnography (PSG). Then at random, some of them will do CPAP titration in the second night followed by HFNC titration in the third night. While others will do HFNC titration in the second night followed by CPAP titration in the third night

Device: Continuous Positive Airway Pressure (CPAP)Device: High Flow Nasal Cannula (HFNC)

Interventions

Continuous Positive Airway Pressure (CPAP) is a form of positive airway pressure ventilation in which a constant level of pressure greater than atmospheric pressure is continuously applied to the upper respiratory tract of an individual.

Participants diagnosed with Obstructive Sleep Apnea

High Flow Nasal Cannula (HFNC) is an oxygen supply system capable of delivering up to 100% humidified and heated oxygen at a flow rate of up to 60 liters per minute

Participants diagnosed with Obstructive Sleep Apnea

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults patient aging above 18 years
  • Diagnosed with Obstructive Sleep Apnea (OSA) based on Polysomnography (PSG) ranging from mild to severe i.e. more than 5

You may not qualify if:

  • Patients with hypoventilation syndrome
  • Patients with chronic obstructive pulmonary disease
  • Patients who have unstable hemodynamic state, who experienced intolerance to HFNC or CPAP
  • Patients who are pregnant
  • Patients recently underwent surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

King Abdulaziz University Hospital

Jeddah, Western, 22230, Saudi Arabia

RECRUITING

Related Publications (1)

  • Wali S, Batawi G, Bin Afeef G, Bamagoos AA, Jamal A, Kanbr O, Alshumrani R, Alhejaili F, Badr MS. The effectiveness of high-flow nasal cannula therapy in comparison with continuous positive airway pressure therapy in patients with obstructive sleep apnea: an open-label randomized crossover trial. J Clin Sleep Med. 2025 Jun 1;21(6):1023-1031. doi: 10.5664/jcsm.11640.

MeSH Terms

Conditions

Sleep Apnea Syndromes

Interventions

Continuous Positive Airway Pressure

Condition Hierarchy (Ancestors)

ApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Intervention Hierarchy (Ancestors)

Positive-Pressure RespirationRespiration, ArtificialAirway ManagementTherapeuticsRespiratory Therapy

Study Officials

  • Siraj O Wali, Professor

    Teaching Assistant at King Abdulaziz University

    STUDY DIRECTOR

Central Study Contacts

Siraj O Wali, Professor

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of Sleep Medicine and Research Center, Professor of Medicine

Study Record Dates

First Submitted

June 22, 2022

First Posted

July 26, 2022

Study Start

June 1, 2022

Primary Completion

December 1, 2022

Study Completion

December 30, 2022

Last Updated

July 26, 2022

Record last verified: 2022-07

Data Sharing

IPD Sharing
Will not share

The study outcome might be shared as well as the methodology

Locations